MLN8237, also known as Alisertib, is a small molecule inhibitor of aurora kinase A (AURKA). It was first synthesized by Millennium Pharmaceuticals in 2003 and has since been studied for its potential as a cancer treatment.
Chemical name:
The chemical name for MLN8237 is N-{(1S)-2-[(9H-purin-6-yl)amino]-1-methylethyl}-2-[(3R)-3-piperidinylmethyl]-1H-benzo[d]imidazole-5-carboxamide.
Molecular formula:
The molecular formula of MLN8237 is C27H20N8O.
Formula weight:
The formula weight of MLN8237 is 464.50 g/mol.
CAS No:
The CAS number of MLN8237 is 1028486-01-2.
Top ten keywords from Google and Synonyms:
Synonyms:
Health benefits of this product:
MLN8237 has been primarily developed for the treatment of cancer. It is a selective inhibitor of AURKA, which plays an important role in cell division and is often dysregulated in cancer cells. By inhibiting AURKA, MLN8237 may help to slow or stop the growth of cancer cells.
Potential effects:
Some potential effects of MLN8237 include:
Product mechanism:
MLN8237 works by inhibiting AURKA, which is a serine/threonine kinase that plays an important role in mitotic spindle assembly and centrosome maturation. AURKA is often overexpressed or mutated in cancer cells, leading to their uncontrolled growth and survival. By inhibiting AURKA, MLN8237 may help to restore normal cellular signaling and slow or stop the growth of cancer cells.
Safety:
MLN8237 has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with MLN8237.
Side effects:
MLN8237 can cause several side effects in some patients. These can include:
Dosing information:
The optimal dosing regimen of MLN8237 has not yet been established and further research is needed to determine the most effective dose. Doses ranged from 10 mg to 50 mg per day in preclinical studies. In clinical trials, doses ranged from 20 mg to 50 mg per day. The drug is typically administered orally.
Conclusion:
MLN8237 is a small molecule inhibitor of AURKA that has shown potential as a treatment for cancer. By inhibiting AURKA, MLN8237 may help to restore normal cellular signaling and slow or stop the growth of cancer cells. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of MLN8237 in treating cancer.
